KLP Kapitalforvaltning AS purchased a new position in Kenvue Inc. (NYSE:KVUE - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 692,246 shares of the company's stock, valued at approximately $14,779,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Handelsbanken Fonder AB grew its stake in shares of Kenvue by 2.9% in the 4th quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock valued at $15,846,000 after buying an additional 21,222 shares during the period. Alberta Investment Management Corp boosted its holdings in Kenvue by 23.2% in the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock worth $12,445,000 after acquiring an additional 109,700 shares in the last quarter. Longbow Finance SA grew its stake in Kenvue by 5.0% in the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after acquiring an additional 13,287 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in shares of Kenvue by 143.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after acquiring an additional 28,216 shares in the last quarter. Finally, CORDA Investment Management LLC. raised its position in shares of Kenvue by 1.4% during the fourth quarter. CORDA Investment Management LLC. now owns 1,253,096 shares of the company's stock worth $26,754,000 after purchasing an additional 17,466 shares during the period. 97.64% of the stock is owned by institutional investors.
Kenvue Stock Performance
NYSE:KVUE traded up $0.24 during trading hours on Friday, reaching $23.74. The stock had a trading volume of 14,401,327 shares, compared to its average volume of 16,745,932. The stock has a market cap of $45.36 billion, a P/E ratio of 44.78, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The stock has a 50 day simple moving average of $22.32 and a 200 day simple moving average of $22.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date was Wednesday, February 12th. Kenvue's payout ratio is currently 154.72%.
Wall Street Analyst Weigh In
Several analysts recently issued reports on KVUE shares. Evercore ISI began coverage on shares of Kenvue in a research report on Monday. They issued an "in-line" rating and a $25.00 price target for the company. Barclays raised their price target on shares of Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a research report on Thursday. Piper Sandler lifted their price target on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research note on Monday, February 24th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research note on Monday, February 3rd. Finally, UBS Group decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Kenvue currently has an average rating of "Hold" and a consensus target price of $24.00.
Read Our Latest Analysis on Kenvue
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Articles
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
